Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical resection specimens will then be analyzed for biological alterations.
Cutaneous Squamous Cell Carcinoma
DRUG: Pramlintide
Participant Compliance, Patients who complete at least 75% of the injections and have not missed 2 consecutive days of treatment will be considered compliant., at 14 days from on study date
Number of Adverse Events, Number of adverse events prior to surgery, during surgery and for 30 days after surgery that may be related to pramlintide injection., at 44 days from on study date
This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical resection specimens will then be analyzed for biological alterations.